ProPhase Labs, Inc. (NASDAQ:PRPH) Short Interest Update

ProPhase Labs, Inc. (NASDAQ:PRPHGet Free Report) was the target of a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 314,200 shares, an increase of 20.8% from the May 15th total of 260,100 shares. Based on an average daily volume of 60,100 shares, the days-to-cover ratio is presently 5.2 days.

ProPhase Labs Trading Down 0.9 %

Shares of ProPhase Labs stock traded down $0.04 during mid-day trading on Monday, hitting $4.55. 27,567 shares of the stock were exchanged, compared to its average volume of 44,334. ProPhase Labs has a twelve month low of $4.05 and a twelve month high of $7.59. The stock has a market capitalization of $86.81 million, a price-to-earnings ratio of -4.25 and a beta of -0.18. The company has a 50-day simple moving average of $5.24 and a 200 day simple moving average of $5.13. The company has a current ratio of 1.88, a quick ratio of 1.73 and a debt-to-equity ratio of 0.31.

ProPhase Labs (NASDAQ:PRPHGet Free Report) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.21. ProPhase Labs had a negative net margin of 82.18% and a negative return on equity of 44.96%. The company had revenue of $3.63 million for the quarter, compared to analysts’ expectations of $9.86 million. During the same period last year, the company earned $0.03 EPS. Research analysts forecast that ProPhase Labs will post -0.82 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on PRPH. HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of ProPhase Labs in a research report on Wednesday, February 21st. StockNews.com raised shares of ProPhase Labs to a “sell” rating in a research note on Monday, May 13th.

View Our Latest Stock Analysis on PRPH

Institutional Investors Weigh In On ProPhase Labs

Several hedge funds have recently modified their holdings of the stock. Tower Research Capital LLC TRC grew its stake in ProPhase Labs by 50.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 15,010 shares of the company’s stock worth $68,000 after buying an additional 5,026 shares during the period. HighTower Advisors LLC purchased a new stake in ProPhase Labs during the third quarter worth approximately $756,000. Finally, Vanguard Group Inc. grew its stake in ProPhase Labs by 1.5% during the first quarter. Vanguard Group Inc. now owns 618,763 shares of the company’s stock worth $4,003,000 after buying an additional 9,416 shares during the period. 9.45% of the stock is owned by institutional investors and hedge funds.

About ProPhase Labs

(Get Free Report)

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.

Recommended Stories

Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.